Application of JAM-A protein to treatment on RA

A JAM-A, rheumatoid technology, used in anti-inflammatory agents, non-central analgesics, bone diseases, etc., can solve problems such as intolerance, adverse reactions in patients, and complex pathogenesis

Inactive Publication Date: 2015-12-09
YUNNAN UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The occurrence and development of rheumatoid arthritis is an autoimmune process involving the lymphatic system and various cytokines. Its pathogenesis is complex and has not yet been fully clarified, and there is a lack of effective clinical treatment methods
At present, the commonly used drugs for the clinical treatment of rheumatoid arthritis are divided into four categories, namely nonsteroidal anti-inflammatory drugs (nonsteroidalanti-inflammatorydrugs, NSAIDs), immunosuppressants, glucocorticoids and herbal medicines, such as methotrexate (methotrexate) aminopterin), azathioprine, cyclophosphamide, etc., but long-term use of these drugs will cause adverse reactions in many patients, resulting in intolerance and discontinuation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of JAM-A protein to treatment on RA
  • Application of JAM-A protein to treatment on RA
  • Application of JAM-A protein to treatment on RA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1: Expression of JAM-A protein in peripheral blood lymphocytes of healthy people and RA patients.

[0020] 1. Collection and grouping of blood samples.

[0021] The peripheral blood sample collected in the present invention informs volunteers and patients with rheumatoid arthritis of the experimental purpose before blood collection and signs an informed consent. review.

[0022] The present invention collected peripheral blood from 48 patients with rheumatoid arthritis (rheumatoid arthritis group, RA), all from the Department of Rheumatology and Immunology, the First Affiliated Hospital of Kunming Medical University. The peripheral blood of 37 healthy adults (normal group, CON) was collected from the First Affiliated Hospital of Kunming Medical University and volunteers of Yunnan University. Each patient and volunteer was asked about the medical history by two attending physicians in the department of rheumatology and immunology and underwent a specialized phy...

Embodiment 2

[0027] Example 2: Expression distribution of JAM-A in peripheral blood of mice with collagen-induced arthritis (CIA).

[0028] 1. Grouping of experimental mice.

[0029] Select 6-8 weeks, C57BL / 6 female mice with a body weight of 22-26 g (Beijing Weitong Lihua Company, clean grade), and randomly divide them into three groups. The first group is the normal control group (Control group, CON). The mice were gavaged with sterilized distilled water once in 3 days, 5 times in total. The second group is the collagen-induced arthritis model group (CIA). The mice are fed with sterilized distilled water once every 3 days, a total of 5 times, and then bovine type II collagen (Chondrex Company, Code No. 20021) is used. Carry out animal immunization to establish arthritis model. The third group is the methotrexate treatment of arthritis group (MTXtreatmentCIAgroup, MTX+CIA), using methotrexate drug for mice every 3 days for 1 gavage, a total of 5 times, followed by bovine type II collage...

Embodiment 3

[0038] Example 3: Effect of JAM-A on lymphocyte migration ability.

[0039] 1. The effect of methotrexate on the expression of junctional adhesion molecule A in lymphocytes.

[0040] Human peripheral blood lymphocytes were treated with methotrexate at three final concentrations of 0.01 μg / mL, 0.1 μg / mL and 1 μg / mL, and the number of lymphocytes inoculated into each well of a 96-well cell culture plate was 4×10 4 , adding 40 μL CellTiter96 at regular interval time points ? AQueousOneSolutionCellProliferationAssay (MTS) (Promega Company, CodeNo.G3580) reagent, after incubation for 4 hours, measure the OD value with a microplate reader. The results found that low concentrations of methotrexate (0.01 μg / mL and 0.1 μg / mL) had no significant effect on the survival of lymphocytes, while high concentrations of methotrexate (1 μg / mL) had a significant effect on the survival of lymphocytes. Significant inhibitory effect (see Figure 7 A-C).

[0041] In addition, lymphocytes treated ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of JAM-A (Junctional Adhesion Molecules A) protein to treatment on RA (Rheumatoid arthritis). The JAM-A whose the expression quantity in peripheral blood lymphocytes of an RA patient is higher than that of a normal healthy person are authenticated; the condition that the JAM-A takes part in the peripheral blood lymphocyte migration regulation in the functional aspect is proved; and the migration of immune lymphocytes to peripheral bones and joints can be effectively weakened, so that the effect of treating the RA is achieved. The identical treatment effect is achieved in a mouse CIA (Collagen Induced Arthritis) animal model. The invention provides a therapeutic molecular target for the clinical intervention on clinic RA patients.

Description

technical field [0001] The invention relates to the expression level and physiological function of Junctional Adhesion Molecules A (JAM-A) protein in lymphocytes of the human immune system; it relates to the regulation of Junctional Adhesion Molecules A (JAM-A) on the migration of peripheral blood lymphocytes and its effect on mouse collagen induction. Model of arthritis induced arthritis (CIA) and its application in the treatment of rheumatoid arthritis (RA). Background technique [0002] Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic synovial inflammation, which eventually leads to cartilage resorption, bone destruction and bone fibrosis. The prevalence of rheumatoid arthritis in the world is 0.42 -0.54%, the disease epidemiological survey in 25 provinces in my country shows that the prevalence rate in my country is 0.32-0.36%. Rheumatoid arthritis is one of the main reasons for the loss of young and middle-aged labor force. Rheumatoid arthrit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/519A61P19/02A61P29/00
Inventor 李梅章丁磊王维陈贵元余敏崔清华
Owner YUNNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap